The goal of the T32 research training program in urologic oncology at Memorial Sloan-Kettering Cancer Center (MSKCC) is to train qualified clinician-scientists to be independent investigators in translational research and to progress to full-time academic positions. Dedicated research training in urologic oncology is essential to the mission of the National Cancer Institute (NCI) to eliminate suffering and death from cancer: genitourinary cancers comprise nearly one third of all non-skin cancers and cause 10% of all cancer deaths in the US. T32 fellows gain direct experience in biomedical research by working full-time for 2 years with established basic and translational research scientists. Fellows are also required to participate in structured, multidisciplinary conferences and to present their work at MSKCC seminars and national meetings. T32 preceptors represent the departments of Surgery, Epidemiology and Biostatistics, Medicine, Radiology, and Pathology, as well as 4 of the major research programs at the Sloan-Kettering Institute: Cell Biology, Immunology, Molecular Biology, and Molecular Pharmacology and Chemistry. Areas of research include cancer genetics;signals and pathways involved in the control of cell proliferation;protein targeting;tumor immunology, immunotherapy, and clinical therapeutics, among others. Although fellows may also undertake 1 year of clinical training, they have no clinical responsibilities during their research years unless it is integral to their research project. Most T32 fellows spend 2.5 to 3.5 years completing all research and clinical training. This T32 training grant will continue to support 4 postdoctoral fellows (typically 2 new and 2 continuing trainees) per year. All T32 candidates must have an MD, must have completed training in urology at a residency program approved by the Accreditation Council for Graduate Medical Education (ACGME), and must be board-eligible urologists. T32 fellows usually enter the program during PGY-6 or PGY-7.

Public Health Relevance

MSKCC's T32 program in urologic oncology trains qualified clinician-scientists for careers focused on eliminating suffering and death from urologic cancers, which comprise 31% of all non-skin cancers and cause 10% of all cancer deaths in the US. To date, 95% of the graduates have matriculated to faculty positions and are engaged in research aimed at understanding and overcoming these cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA082088-15
Application #
8712143
Study Section
Subcommittee B - Comprehensiveness (NCI)
Program Officer
Lim, Susan E
Project Start
1999-09-01
Project End
2015-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
15
Fiscal Year
2014
Total Cost
Indirect Cost
City
New York
State
NY
Country
United States
Zip Code
10065
Manley, Brandon J; Hakimi, Abraham Ari (2016) Molecular profiling of renal cell carcinoma: building a bridge toward clinical impact. Curr Opin Urol 26:383-7
Imnadze, Mariam; Sjoberg, Daniel D; Vickers, Andrew J (2016) Adverse Pathologic Features at Radical Prostatectomy: Effect of Preoperative Risk on Oncologic Outcomes. Eur Urol 69:143-8
Bagrodia, Aditya; Cha, Eugene K; Sfakianos, John P et al. (2016) Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. J Urol 195:1684-9
A, Sankin (2016) Discovering Biomarkers within the Genomic Landscape of Renal Cell Carcinoma. J Kidney 2:
Li, Qiang; Bagrodia, Aditya; Cha, Eugene K et al. (2016) Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma. Curr Urol Rep 17:12
Feuerstein, Michael A; Atoria, Coral L; Pinheiro, Laura C et al. (2016) Patterns of surveillance imaging after nephrectomy in the Medicare population. BJU Int 117:280-6
Feuerstein, Michael A; Musser, John E; Kent, Matthew et al. (2016) Low yield of surveillance imaging after surgery for T1 kidney cancer. World J Urol 34:949-53
Kaffenberger, Samuel D; Barbieri, Christopher E (2016) Molecular subtyping of prostate cancer. Curr Opin Urol 26:213-8
Hakimi, A Ari; Ostrovnaya, Irina; Jacobsen, Anders et al. (2016) Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. Cancer 122:402-10
Sankin, Alexander; Tin, Amy L; Mano, Roy et al. (2016) Impact of Ureteroscopy Before Nephroureterectomy for Upper Tract Urothelial Carcinoma on Oncologic Outcomes. Urology 94:148-53

Showing the most recent 10 out of 175 publications